glp 1 vs glp 1ra Understanding GLP-1 receptor agonists and their impact on drug discovery Mapping the effectiveness and risks

Even insured users report difficulty affording them, over half of whom find them somewhat or very hard to pay for

doi: 10.1016/j.molmet.2021.101240 88 LudwigMQChengWGordianDLeeJPaulsenSJHansenSNet al

The lesser degree of weight gain in the WD+allulose group suggests a potential protective effect of allulose against diet-induced obesity

Belly fat, the deep visceral kind, is part of that conversation, and its tied to blood pressure, blood sugar, and overall metabolic health

A person eating 2,500 calories a day has a wide margin for nutritional error

Unlike the FDA-approved dosing regimen for GLP-1s, there is no published evidence to support microdosing these medications to achieve weight loss